Abstract
The optimum treatment of primary CNS lymphoma (PCNSL) is not yet determined. The objective of this study was to assess the safety and efficacy of initial methotrexate-based chemotherapy followed by high-dose chemotherapy (HDT) with autologous stem cell transplantation (ASCT) in patients with newly diagnosed PCNSL. Twenty-five patients received two courses of initial chemotherapy combining methotrexate, etoposide, carmustine and methylprednisolone, and one course of ifosfamide–cytarabine followed by peripheral stem cell collection. Seventeen responsive patients then received HDT using carmustine, etoposide, cytarabine and melphalan with autologous stem cell rescue. After ASCT for responding patients or after salvage therapy for non-responders, whole brain radiation therapy at a dose of 30 Gy was delivered. The objective response rate to the induction chemotherapy was 84%. Four of the 21 responding patients did not have ASCT because of toxicity or refusal. With a median follow-up time of 34 months, the projected event free survival rate is 46% at 4 years. Projected overall survival is 64% at 4 years. Sixteen patients are actually in continuous complete response. No evidence of late treatment-related toxicity was observed. This treatment approach appears feasible in newly diagnosed PCNSL with encouraging results.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Abrey LE, Deangelis LM, Yalahom J . Long term survival in primary CNS lymphoma. J Clin Oncol 1998; 16: 359–363.
Deangelis LM, Seiherfeld W, Schold S, Fisher B, Schultz JS . Combination chemotherapy and radiotherapy for primary central nervous system lymphoma: Radiation Therapy Oncology Group Study 93-10. J Clin Oncol 2002; 20: 4643–4648.
Hoang-Xuan K, Taillandier L, Chinot O, Soubeyran P, Bogdhan V, Mildebrand J et al. Chemotherapy alone as initial treatment for primary CNS lymphoma in patients older than 60 years: a multicenter phase II study of the European Organisation for Research and Treatment of Cancer Brain Tumor Group. J Clin Oncol 2003; 21: 2726–2731.
Soussain C, Suzan F, Hoang-Xuan K, Cassaux N, Levy V, Azar N et al. Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma. J Clin Oncol 2001; 19: 742–749.
Khalfallah S, Stamatoullas A, Fruchart C, Proust F, Dewangre T, Tilly H . Durable remission of a relapsing primary central nervous system lymphoma after autologous bone marrow transplantation. Bone Marrow Transplant 1996; 18: 1021–1023.
Bessell M, Lopez-Guillermo A, Villa S, Verger E, Nomdedeu B, Petit J et al. Importance of radiotherapy in the outcome of patients with primary CNS lymphoma: an analysis of the CHOD/VBAM regimen followed by two different radiotherapy treatments. J Clin Oncol 2002; 20: 231–236.
Abrey LE, Yalahom J, Deangelis LM . Treatment of primary CNS lymphoma: the next step. J Clin Oncol 2000; 18: 3144–3150.
Abrey LE, Moskowitz CH, Mason WP, Crump M, Stewart D, Forsyth P et al. Intensive methotrexate and cytarabine followed by high-dose chemotherapy with autologous stem-cell rescue in patients with newly diagnosed primary CNS lymphoma: an intent-to treat analysis. J Clin Oncol 2003; 21: 4151–4156.
Cheng T, Forsyth P, Chaudhry A, Morris D, Gluck S, Russel JA et al. High-dose thiotepa, busulfan, cyclophosphamide and ASCT without whole-brain radiotherapy for poor prognosis primary CNS lymphoma. Bone Marrow Transplant 2003; 31: 679–685.
Ferreri AJM, Blay JY, Reni M, Pasini F, Spina M, Ambrosetti A et al. Prognostic scoring system for primary CNS lymphomas: the international extranodal lymphoma study group experience. J Clin Oncol 2003; 21: 266–272.
Acknowledgements
We thank MC Chamard and Dr L Benboubker for their technical assistance. This work was supported by the Ministry of Health (France) and Schering-Plough pharmaceutical Company (Kenniworth, USA).
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Colombat, P., Lemevel, A., Bertrand, P. et al. High-dose chemotherapy with autologous stem cell transplantation as first-line therapy for primary CNS lymphoma in patients younger than 60 years: a multicenter phase II study of the GOELAMS group. Bone Marrow Transplant 38, 417–420 (2006). https://doi.org/10.1038/sj.bmt.1705452
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.bmt.1705452
Keywords
This article is cited by
-
High-dose methotrexate and rituximab induction regimen in immunocompetent patients with primary CNS lymphoma: a retrospective single-center study of survival predictors
Journal of Neuro-Oncology (2022)
-
Intensive chemotherapy followed by autologous stem cell transplantation in primary central nervous system lymphomas (PCNSLs). Therapeutic outcomes in real life—experience of the French Network
Bone Marrow Transplantation (2022)
-
Consolidation Therapy in Primary Central Nervous System Lymphoma
Current Treatment Options in Oncology (2020)
-
Hematopoietic stem cell transplantation in primary central nervous system lymphoma: a review of the literature
International Journal of Hematology (2019)
-
Thiotepa, busulfan, and cyclophosphamide or busulfan, cyclophosphamide, and etoposide high-dose chemotherapy followed by autologous stem cell transplantation for consolidation of primary central nervous system lymphoma
Annals of Hematology (2019)
